PE firm Ampersand acquires German CDMO Vibalogics

By Maggie Lynch

- Last updated on GMT

(Image: Getty/mikdam)
(Image: Getty/mikdam)

Related tags CDMO Ampersand Capital PE acquistion development Manufacturing Gmp Gene therapy

The private equity firm Ampersand Capital has acquired Vibalogics with plans to increase development and manufacturing capabilities for complex viral products.

Through the acquisition, the middle market private equity (PE) firm will work to expand Vibalogics capabilities to meet the industry’s demand through investments in additional process development and manufacturing capabilities.

The German contract development and manufacturing organization (CDMO) provides services for biopharmaceutical companies working to develop oncolytic viral therapies, gene therapies, and vaccines, specifically focusing on viruses, live bacteria, and aseptic processing.

Vibalogic’s 27,000 square-foot facility in Cuxhaven, Germany has four independent good manufacturing practice (GMP) production suites, and all laboratories meet BSL-2 standards.

David Anderson, general partner at Ampersand explained, “Given the exciting developments within the complex virus market this is an excellent time for an investor with deep experience in the viral vector contract manufacturing sector to partner with the company.”

Stefan Bayer, CEO of Vibalogics, said in a statement that with this partnership Vibalogics will also be able to strengthen and expand its position in the US and European markets.

Ampersand’s current portfolio includes other service providers such as Brammer Bio, Avista Pharma, Bioventus, MedPharm, and KeyBiologics.

Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Designing an Optimal APAC Clinical Supply Chain

Designing an Optimal APAC Clinical Supply Chain

Catalent | 08-Mar-2023 | Infographic

With clinical study activity increasing across the Asia-Pacific region, it is important for sponsors—both in APAC and globally—to understand the broader...

2023 State of Clinical Trial Technology Report

2023 State of Clinical Trial Technology Report

Florence Healthcare | 01-Mar-2023 | Insight Guide

Discover the trends shaping clinical trial technology in 2023, from Site Enablement to eISFs, integrations, and site-sponsor collaboration. This report...

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Thermo Fisher Scientific - Process Liquid Preparation Services | 21-Feb-2023 | Technical / White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us

Products

View more

Webinars